Keyword: Imfinzi (durvalumab)
After watching from the sidelines as its rivals dove into I-O’s most coveted market, AstraZeneca finally has a win in previously untreated NSCLC.
Tagrisso, Lynparza and Imfinzi, as well as China, have teamed up for growth at AstraZeneca. But each faces its own fight just around the corner.
Roche’s Tecentriq is the only I-O drug approved in small cell lung cancer. But it may soon have to make some room for AstraZeneca’s Imfinzi.
AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.
With PARP inhibitors on the up-and-up in BRCA-mutated ovarian cancer, AstraZeneca’s Lynparza just got a leg up from England’s cost watchdog.
AstraZeneca’s cancer meds put on another good show, with PD-L1 drug Imfinzi and Merck & Co.-shared Lynparza both headed for the blockbuster line.
AstraZeneca wants to double the five-year lung cancer survival rate by 2025. The disease is the leading cause of cancer deaths in the U.S.
AstraZeneca has some good news to report in lung cancer. But it's from the small cell lung cancer field where Roche’s Tecentriq is a step ahead.
Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.
AstraZeneca and pro golfer Jason Day have teamed up on a campaign to encourage biomarker testing for lung cancer patients.